Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track ELAB with free AI briefings, catalyst countdowns, and dilution alerts.

ELAB · PMGC Holdings Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$18.8M Cash on Hand
22.7mo Cash Runway
Follow ELAB by email Get an email when ELAB reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about ELAB, unsubscribe in one click. Privacy

📣 What ELAB Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

💰 Cash Runway & Dilution Risk

ELAB holds $18.8M in cash and short-term investments (as of Jun 30, 2026) and burns about $2.5M/quarter from operations, an estimated runway of 22.7 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 68 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ELAB files for a raise →

👥 Who Owns ELAB

Insiders 100% Institutions (8 holders) 0% Public and other holders 0%
HolderTypeShares% of sharesAs of
Jordan R. Plews
CEO, Director, 10% owner
Insider 2,993,120 256.06% 2023-11-13
JP Bio Consulting LLC
CEO, Director, 10% owner
Insider 2,851,454 243.94% 2023-11-13
PMGC Holdings Inc. 5%+ holder (13D) 2,402,463 205.53% 2026-10-20
NorthStrive Sponsor I LLC
10% owner
Insider 2,170,713 185.70% 2026-10-20
BWL Investments Ltd.
10% owner
Insider 1,967,965 168.36% 2023-12-28
Hatem Abou-Sayed
Director
Insider 1,513,571 129.48% 2023-11-13
Hatem Abou-Sayed MD MBA FACS, a Professi
CMO, Director
Insider 1,371,905 117.36% 2023-11-13
GB Capital Ltd.
CFO, Director
Insider 841,454 71.98% 2023-11-13
Lichti Braeden
Director · +450,281 options
Insider 450,313 38.52% 2026-06-01
Graydon Bensler
Chief Executive Officer, Director · +450,279 options
Insider 450,287 38.52% 2026-06-01
Brenda Beuchler
CMO
Insider 56,226 4.81% 2023-11-13
Chris Kraneiss
CMO
Insider 31,250 2.67% 2023-11-13

Share count 1,168,935 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full ELAB picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ELAB and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.